Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer Текст научной статьи по специальности «Клиническая медицина»

South Russian Journal of Cancer. 2024. Vol. 5, No. 4. P. 6-13 4.0

https://doi.org/10.37748/2686-9039-2024-5-4-1

https://elibrary.ru/ohijav

South Russian

Journal of Cancer ORIGINAL ARTICLE

Южно-Российский

онкологический журнал

Vol. 5

No. 4, 2024 Intravenous radionuclide therapy with radium chloride [223Ra] in

patients with bone metastases from castration-resistant prostate cancer

O. I. Kit, N. A. Maksimova, M. A. Gusareva, A. N. Shevchenko, M. S. Zinkovich, M. G. Ilchenko,

K. P. Boyko, A. V. Faenson, S. N. Dimitriadi, L. Ya. Rozenko

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

 [email protected]

ABSTRACT

Purpose of the study. Assessment of clinical safety and effectiveness of radium-223 in patients with bone metastases from

castration-r esistant prostate cancer.

Patients and methods. The study involved materials on 15 patients with bone metastases from castration- resistant prostate

cancer aged 58–81 years, with the mean age of 67.2 ± 6.5 years, who were examined and received full treatment with 6

intravenous injections of radium-223 chloride [223Ra] at the National Medical Research Centre for Oncology. Most patients

(73.3 %) showed ECOG 1 performance status. Pain syndrome before the treatment was registered in 12 (80 %) patients.

Results. Evaluation of the tolerability of radium chloride did not show hematological reactions such as anemia and thrombo-

cytopenia. One patient had grade II intestinal toxicity after the 3rd injection managed with medication. Assessment of indirect

signs of the treatment effectiveness demonstrated that 6 people showed an increase in PSA during treatment, while alkaline

phosphatase levels were within normal range indicating no bone destruction. 8 of 12 patients with pain syndrome showed

its relief during the therapy. The following results were obtained during a follow-up examination after 3 months in 15 patients

who received the full treatment course: stabilization in 8 patients; improvement in 4 patients with decreased metabolic activity

and lower numbers of metastatic foci; progression with the appearance of new metastatic foci in the bones in 3 patients.

Conclusion. Radium chloride showed good results in the treatment of patients with bone metastases from castration- resistant

prostate cancer. Low toxicity and improvement in the quality of life by pain relief make this treatment technique promising.

Keywords: castration-resistant prostate cancer, bone metastases, radium chloride [223Ra], quality of life

For citation: Kit O. I., Maksimova N. A., Gusareva M. A., Shevchenko A. N., Zinkovich M. S., Ilchenko M. G., Boyko K. P., Faenson A. V., Dimitriadi S. N.,

Rozenko L. Ya. Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer.

South Russian Journal of Cancer. 2024; 5(4): 6-13. https://doi.org/10.37748/2686-9039-2024-5-4-1, https://elibrary.ru/ohijav

For correspondence: Maria G. Ilchenko – Cand. Sci. (Med.), MD, Researcher at the Department of Tumor Diagnostics, National Medical Research Centre for

Oncology, Rostov-on-Don, Russian Federation

Address: 63 14 line str., Rostov-on-Don 344037, Russian Federation

E-mail: [email protected]

ORCID: https://orcid.org/0000-0002-9126-0646

SPIN: 2856-7946, AuthorID: 734046

ResearcherID: ААТ-9807-2020

Compliance with ethical standards: the ethical principles presented by the World Medical Association Declaration of Helsinki, 1964, ed. 2013, were observed

in the work. The study was approved by the Committee on Biomedical Ethics at the National Medical Research Centre for Oncology (extract from the protocol

of the meeting No. 7 dated 08/08/2022). Informed consent was received from all participants of the study.

Funding: this work was not funded

Conflict of interest: Kit O. I. has been the member of the editorial board of the South Russian Journal of Cancer since 2019, however he has no relation to

the decision made upon publishing this article. The article has passed the review procedure accepted in the journal. The authors did not declare any other

conflict of interest

The article was submitted 01.12.2023; approved after reviewing 12.10.2024; accepted for publication 30.10.2024

© Kit O. I., Maksimova N. A., Gusareva M. A., Shevchenko A. N., Zinkovich M. S., Ilchenko M. G., Boyko K. P., Faenson A. V., Dimitriadi S. N., Rozenko L. Ya., 2024

6

Южно-Российский онкологический журнал. 2024. Т. 5, № 4. С. 6-13

https://doi.org/10.37748/2686-9039-2024-5-4-1

https://elibrary.ru/ohijav

3.1.6. Онкология, лучевая терапия

ОРИГИНАЛЬНАЯ СТАТЬЯ

Применение внутривенной радионуклидной терапии радия хлоридом [223Ra]

у пациентов с костными метастазами кастрационно-резистентного рака

предстательной железы

О. И. Кит, Н. А. Максимова, М. А. Гусарева, А. Н. Шевченко, М. С. Зинькович, М. Г. Ильченко, К. П. Бойко,

А. В. Фаенсон, С. Н. Димитриади, Л. Я. Розенко

ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации,

г. Ростов-на-Дону, Российская Федерация

 [email protected]

РЕЗЮМЕ

Цель исследования. Оценка клинической безопасности и эффективности применения радия-223 у пациентов с кост-

ными метастазами кастрационно-р езистентного рака предстательной железы (РПЖ).

Материалы и методы. В исследование включены сведения о 15 пациентах с костными метастазами кастрационно-

резистентного РПЖ в возрасте от 58 до 81 года, средний возраст 67,2 ± 6,5 года, обследованных и получивших полный

курс лечения из 6 внутривенных радиотерапий препаратом радия хлорида [223Ra] на базе ФГБУ «Национальный

медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации. Функ-

циональное состояние большей части пациентов (73,3 %) соответствовало 1 по шкале ECOG. Перед началом лечения

болевой синдром отмечался у 12 (80 %) пациентов.

Результаты. При оценке переносимости радия хлорида было отмечено отсутствие гематологических реакций,

таких как анемия и тромбоцитопения. У одного пациента была отмечена кишечная токсичность II степени, которая

появилась после 3-го введения и была медикаментозно купирована. Оценка косвенных признаков эффективности

проведенного лечения: у 6 человек за время лечения был отмечен рост простатического специфического антигена

(ПСА), при этом показатели уровня щелочной фосфатазы находились в пределах нормы, что может говорить об

отсутствии костной деструкции. У 8 из 12 человек с болевым синдромом наблюдалось его снижение уже на этапе

терапии. У 15 пациентов, получивших полный курс лечения, при контрольном обследовании через 3 месяца были

получены следующие результаты: у 8 человек – стабилизация процесса, у 4 человек – улучшение в виде снижения

уровня метаболической активности и уменьшение количества метастатических очагов, у 3 пациентов отмечено

прогрессирование заболевания с появлением новых метастатических очагов в костях скелета.

Заключение. Радия хлорид показал хорошие результаты в терапии пациентов с костными метастазами кастрационно-

резистентного рака предстательной железы. Низкие уровни токсичности и возможность улучшить качество жизни за

счет снижения выраженности болевого синдрома позволяют говорить о перспективности данной лечебной методики.

Ключевые слова: кaстрaционнo-резистентный рaк предстaтельной желeзы, метaстазы в кoсти, радия хлорида

[223Ra], качество жизни

Для цитирования: Кит О. И., Максимова Н. А., Гусарева М. А., Шевченко А. Н., Зинькович М. С., Ильченко М. Г., Бойко К. П., Фаенсон А. В.,

Димитриади С. Н., Розенко Л. Я. Применение внутривенной радионуклидной терапии радия хлоридом [223Ra] у пациентов с костными

метастазами кастрационно-резистентного рака предстательной железы. Южно-Российский онкологический журнал. 2024; 5(4): 6-13.

https://doi.org/10.37748/2686-9039-2024-5-4-1, https://elibrary.ru/ohijav

Для корреспонденции: Ильченко Мария Геннадьевна – к.м.н., научный сотрудник отдела диагностики опухолей, ФГБУ «Национальный

медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону,

Российская Федерация

Адрес: 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

E-mail: [email protected]

ORCID: https://orcid.org/0000-0002-9126-0646

SPIN: 2856-7946, AuthorID: 734046

ResearcherID: ААТ-9807-2020

Соблюдение этических стандартов: в работе соблюдались этические принципы, предъявляемые Хельсинкской декларацией Всемирной

медицинской ассоциации (World Medical Association Declaration of Helsinki, 1964, ред. 2013). Исследование одобрено Комитетом по

биомедицинской этике при ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской

Федерации (выписка из протокола заседания № 7 от 08.08.2022). Информированное согласие получено от всех участников исследования.

Финансирование: финансирование данной работы не проводилось

Конфликт интересов: Кит О. И. является членом редакционной коллегии журнала «Южно-Российский онкологический журнал» с 2019 г., но не имеет

никакого отношения к решению опубликовать эту статью. Статья прошла принятую в журнале процедуру рецензирования. Об иных конфликтах

интересов авторы не заявляли

Статья поступила в редакцию 01.12.2023; одобрена после рецензирования 12.10.2024; принята к публикации 30.10.2024

7

South Russian Journal of Cancer 2024. Vol. 5, No. 4. P. 6-13

Kit O. I., Maksimova N. A., Gusareva M. A., Shevchenko A. N., Zinkovich M. S., Ilchenko M. G., Boyko K. P., Faenson A. V., Dimitriadi S. N., Rozenko L. Ya. Intravenous

radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer

INTRODUCTION early as possible before their appearance. When ra-

dium chloride [223Ra] is prescribed for the diagnosis

Prostate cancer (prostate cancer) ranks second of bone metastases, the results of osteoscintigraphy

in the structure of cancer incidence in the male pop- are of fundamental importance, which does not re-

ulation and is one of the leading causes of cancer quire the use of additional research methods such

mortality in the world [1, 2]. Its share is 15.1 % in the as CT or MRI [6, 8].

structure of the incidence of malignant neoplasms in The purpose of the study was to evaluate the clini-

the male population in Russia [1]. Over 10 years, the cal safety and efficacy of radium-223 in patients with

increase in Russia amounted to 41.69 %, so in 2021, bone metastases of castration- resistant prostate

the incidence of prostate cancer almost doubled cancer.

compared to 2011 and reached 59.24 per 100,000

population  [1]. The mortality rate in Russia from MATERIALS AND METHODS

prostate cancer remains high, in 2021 it is 19.03

per 100,000 population, an increase of 23.87 % over The study included 15 patients who received ther-

10 years [1]. In Russia, up to 50 % of patients suf- apy with the drug "Xofigo" radium chloride [223Ra]

fering from prostate cancer are already treated with at the National Medical Research Centre for Oncol-

advanced stages III–IV of the disease, metastatic ogy. The average age of the patients was 67.2 years

cancer accounts for up to 18.1 % of patients [3, 4]. (ranged from 58–81 years). The objective status of

It is generally accepted for patients with prostate the majority of patients on the ECOG scale corre-

cancer to undergo hormonal treatment in the form of sponded to 1 (73.3 %) [9]. Patients were assessed

maximum androgenic blockade, including pharmaco- for pain intensity before treatment and before each

logical castration. The development of resistance to course of radiotherapy using a visual analog pain

the therapy leads to the progression of the disease scale (VAS) [6]. VAS is a straight-line segment 10 cm

with a fatal outcome. According to literature data, long. Its beginning corresponds to the absence of

castration-r esistant prostate cancer (CRPC) develops pain – "there is no pain", and the end point reflects ex-

within 5 years of treatment in 10–20 % of patients. cruciating unbearable pain – "unbearable pain". The

Currently, the issue of finding methods to overcome line can be either horizontal or vertical. The patient

castration resistance remains relevant, since the ap- was asked to make a mark on it corresponding to

pearance of bone metastases, the generalization of the intensity of the pain he was experiencing at the

the process is accompanied by a significant deterio- moment. The distance between the beginning of the

ration in the quality of life of patients and an increase segment ("there is no pain") and the mark made is

in overall mortality rates from prostate cancer [2, 5]. measured in centimeters and rounded to the whole.

The property of radium chloride [223Ra] to com- Each centimeter on the line corresponds to 1 point.

petitively bind to bone hydroxyapatites makes it pos- At a mark of up to 2 cm, the pain is classified as mild,

sible to use it as an osteotropic radiopharmaceuti- from 2 to 4 cm – moderate, from 4 to 6 cm – severe,

cal therapy (RPT) in the presence of metastatic foci from 6 to 8 cm – the strongest and up to 10 cm –

in skeletal bones associated with increased bone unbearable. At the time of initiation of therapy, pain

mineralization [6]. Radium chloride [223Ra] is an ap- syndrome of varying severity was noted in 12 pa-

proved drug for the treatment of CRPC with direct ef- tients (80 %). Radium-223 was received as 1st-line

fects on foci in metastatic bone lesions. Radium-223 therapy by 4 patients (26.7 %), 2nd-line – 7 people

is recognized as the drug of choice in patients with (46.6 %), 3rd-line – 4 patients (26.7 %). All patients

CRPC in the presence of bone metastases of the 1st received a full course of radiotherapy – monthly in-

and subsequent lines of therapy according to the travenous injections of radiopharmaceutical radium

recommendations of the European Association of chloride [223Ra] for 6 months in the required vol-

Urologists (high degree of recommendation) [6, 7] ume [9]. In total, 90 patients underwent intravenous

and the National Cancer Control Network (1st level radiotherapy with radium chloride [223Ra].

of evidence) in 2020. Since radium chloride thera- Radium chloride solution [223Ra] is a radium solu-

py [223Ra] the presence of visceral metastases is tion in ionic form with an activity of 1100 kBq/ml.

a contraindication to its use, it should be used as The specific activity of radium-223 is 1.9 MBq/ng.

8

Южно-Российский онкологический журнал 2024. Т. 5, № 4. С. 6-13

Кит О. И., Максимова Н. А., Гусарева М. А., Шевченко А. Н., Зинькович М. С., Ильченко М. Г., Бойко К. П., Фаенсон А. В., Димитриади С. Н., Розенко Л. Я.

Применение внутривенной радионуклидной терапии радия хлоридом [223Ra] у пациентов с костными метастазами кастрационно-резистентного рака

предстательной железы

The half-life of radium is 223 11.4 days. At the stag- then the activity in the unopened vial was measured

es of the decay of radium-223 to stable lead, alpha, and the required volume of the drug was collected

beta and gamma particles are emitted with an al- into a syringe. The activity in the syringe was mea-

pha radiation energy value of 95.3 % (energy range sured and the drug was administered intravenously

5.0–7.5 MeV), 3.6 % beta radiation (energy range slowly. After administration, the dose rate of photon

0.45–0.49 MeV) and 1.1 % gamma radiation (energy radiation was determined at 1.0 meters from the

range 0.01–1.27 MeV) [10] Being a competitor of cal- patient's body with the injected RPT activity at the

cium, radium-223 selectively affects bone metasta- exit from the unit, which should not exceed 3 mSv/h

ses in prostate cancer, forming a complex compound (NRB-99). The measured doses of photon radiation

with the bone mineral hydroxyapatite. The therapeu- in all patients were within the acceptable standard

tic effect is because of alpha particles, which have parameters, on average 0.83 mSv/h.

a cytotoxic effect on tumor cells and microenviron- After intravenous radiotherapy of radium chlo-

ments (osteoclasts, osteoblasts). The high energy ride  [223Ra], the patient was provided with the

of radium chloride alpha particles (80 keV/µm) and necessary protocols and medical documents with

the low range of action – less than 100 µm (less than recommendations on the peculiarities of behavior,

10 cell diameters) make treatment safe with minimal considering radiation safety standards.

damage to healthy tissues [10, 11].

Due to its good tolerability and minimal side ef- STUDY RESULTS

fects, the treatment of bone metastases with radium

isotope does not require special preparations. The A  full course of treatment (6 injections of radi-

main amount is excreted through the intestines and um-223) was performed in 15 patients. Radium-223

about 5 % of the drug is excreted by the kidneys. showed low levels of toxicity, so hematological reac-

For these reasons, on the day of administration, we tions (anemia, thrombocytopenia) were not observed

recommended using products that do not have an in any patient. The level of alkaline phosphatase was

irritating effect on the intestinal mucosa and im- within the normal range before and during treatment.

mediately before administration, we recommended In 6 patients (40 %), an increase in PSA levels by more

drinking about 1 liter of water to reduce the load than 100 % was noted during treatment, which, ac-

on the urinary system. And, a few days before the cording to the literature, is not a reliable indicator of

introduction of the isotope, it was recommended progression and does not require a change in the line

to stop taking drugs containing calcium or vitamin of therapy [10]. One patient (6.6 %) had grade 2 intes-

D because of the possibility of its interaction with tinal toxicity after the 3rd administration, which was

calcium and phosphates [10, 12]. medically stopped and did not recur. Of the 12 patients

The method of therapy: a full course of radium with pain syndrome, 8 (66.6 %) had a decrease after

chloride treatment [223Ra], consisting of 6 injec- 3–4 intravenous radiotherapy sessions with radium

tions of the isotope with an interval of 28 days, is chloride [223Ra]. So, before the start of radiothera-

designed for six months. Before each course of py, 2 patients (16.6 %) noted pain by 8 on the scale,

treatment, we monitored blood counts [10, 13]. The 4 people (33.3 %) gave 7 points, 3 patients (25 %) gave

drug was administered intravenously slowly, at the 6 points, 2 (16.6 %) – 5 points and 1 (8.3 %) – 4 points.

rate of 55 kBq / kg, through a peripheral or central After completing 6 courses, all patients assessed a de-

venous catheter. crease in pain intensity by almost two times (Fig. 1).

We calculated the required dose of activity us- In patients who received a full course of treat-

ing the formula: the patient's body weight (kg) ment, the following results were obtained during

× 55 (kBq / kg) = activity (kBq), then the required a control examination after 3 months: stabilization

volume of RPT was determined by the formula: ac- of the process in 8 people (53.3 %), improvement

tivity (kBq)/ (1100 kBq/ml × radioactive decay co- in 4 people (26.6 %) in the form of a decrease in

efficient) = volume of the drug (ml). The activity in metabolic activity and a decrease in the number of

the vial at the date of administration was calculated metastatic foci, and only 3 patients (20 %) revealed

using the formula: 6600 kBq × decay factor = ac- the progression of the disease in the form of the

tivity in the vial on the day of administration (kBq), appearance of new foci.

9

South Russian Journal of Cancer 2024. Vol. 5, No. 4. P. 6-13

Kit O. I., Maksimova N. A., Gusareva M. A., Shevchenko A. N., Zinkovich M. S., Ilchenko M. G., Boyko K. P., Faenson A. V., Dimitriadi S. N., Rozenko L. Ya. Intravenous

radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer

A clinical example nodes on the right side up to 3 cm. Osteoscintig-

Patient R., born in 1962, presented with castration- raphy dated 07/15/2019 showed no scintigraphic

resistant prostate cancer sT2cN1M0, st.IV, after signs of osteodestructive changes in the bones of

hormonal and radiation therapy, progression (bone the skeleton. Hormonal therapy in the amount of

metastases), bisphosphonate therapy and 6 courses maximum androgenic blockade for 12 months was

of systemic radionuclide therapy (Ra 223), cl. gr. 2. administered. PSA on 07/12/20 was 0.230 ng/ml.

From the anamnesis: during a routine examination, From 08/10/2020 to 09/04/2020, the course of con-

an increase in PSA to 75 ng/ml was noted in June formal remote radiation therapy to a total focal dose

2019. Prostate biopsy of G. A. No. 7243–7254 mod- (TFD) of 75 Gy per area of the prostate gland and

erately differentiated adenocarcinoma, Gleason index seminal vesicles, up to TFD 50 Gy per pelvic area.

7 (4 + 3) was concluded on 06/20/2019. In magnetic MRI from 04/22/2021 showed MR-signs of hyper-

resonance computed tomography from 07/04/2019: plasia of the prostate gland transitional zone. The

lesion of both lobes of the prostate gland without presence of index foci was not revealed. The focus

the tumor leaving the capsule, internal iliac lymph in S1 of the sacrum (possibly mts) requires dynamic

8

6

4

2

0

1 2 3 4 5 6 7 8 9 10 11 12

 after treatment  before treatment

Fig. 1. Results of pain intensity assessment before and after 6 courses of intravenous radiotherapy with radium chloride [223Ra]

Fig. 2. Bone scintigraphy before the treatment Fig. 3. Bone scintigraphy after the treatment

10

Южно-Российский онкологический журнал 2024. Т. 5, № 4. С. 6-13

Кит О. И., Максимова Н. А., Гусарева М. А., Шевченко А. Н., Зинькович М. С., Ильченко М. Г., Бойко К. П., Фаенсон А. В., Димитриади С. Н., Розенко Л. Я.

Применение внутривенной радионуклидной терапии радия хлоридом [223Ra] у пациентов с костными метастазами кастрационно-резистентного рака

предстательной железы

control. Osteoscintigraphy (05/07/2021): there is After the third administration, there was a signifi-

a pronounced uneven distribution of radiopharma- cant decrease in the severity of the pain syndrome,

ceutical (RPT) with signs of focal lesion: 7 ribs on after the sixth administration, only minor discomfort

the right – 45 %, 9 ribs on the left – 55 %, iliac root was noted. Osteoscintigraphy dated 01/26/2023

70 %. Hormonal therapy and bisphosphonates were showed scintigraphic signs of local osteodestruc-

prescribed. SCT (06/02/2022) showed lung tissue tive changes in the bones of the skeleton, in projec-

without foci. The intrathoracic lymph nodes were not tion of the 7th rib on the right (18 %), and the right

enlarged. There is no data for visceral metastases. ilium (16 %) (Fig. 3).

There is no ascites. Retroperitoneal lymph nodes As we can clearly see there is a pronounced pos-

are not enlarged. Metastatic lesion of the 7th rib on itive shift.

the right. Osteoscintigraphy (06/07/2022) revealed

signs of local osteodestructive changes in the pro- CONCLUSION

jection of 7 ribs on the right – 48 %, 9 ribs on the

left – 35 %, right iliac bone – 64 % (Fig. 2.). There Even though it is too early to talk about statisti-

was a complaint of pain in the pelvic bones. From cally significant conclusions, a number of positive

07/28/2022 to 12/13/2022, at the National Medical aspects related to radium chloride 223Ra therapy

Research Centre for Oncology, the patient underwent can already be noted. First, a decrease in the severity

6 courses of systemic radionuclide therapy sessions of pain syndrome and, as a result, an improvement

with radium chloride [223Ra]. The patient tolerated in the quality of life in patients with bone metasta-

treatment adequately, no toxic reactions from the ses of castration- resistant prostate cancer. A low

treatment were observed. According to laboratory degree of severity of adverse and toxic reactions

studies, there was an increase in PSA throughout was noted, which is important, since most patients

the course. are elderly people with severe concomitant pathol-

Total PSA on 07/25/2022 was 2.07 ng/ml; ogy. The results obtained using objective research

on 08/23/2022–3.65 ng/ml; on 09/19/2022– methods are comparable with the data of domestic

6.55  ng/ ml; on 10/14/2022–8.03 ng/ml; on and foreign authors and indicate the prospects of

11/11/2022–8.5 ng/ml; on 12/9/2022–9.54 ng/ml. this therapeutic technique.

References

1. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Ed. by A. D. Kaprin, V. V. Starinsky, A. O. Shakhzadova.

Moscow: P. A. Herzen MNIOI – Branch of the National Medical Research Radiological Center, 2022, 252 p. (In Russ.)

2. Andreev DA, Zavyalov AA, Govorov AV, Kokushkin KA, Davydovskaya MV. Castration-resistant prostate cancer: new per-

spectives in pharmacological treatment. Russian Medical Journal. 2019;25(1):49–58. (In Russ.).

https://doi.org/10.18821/0869-2106-2019-25-1-49-58, EDN: VPCCJR

3. Markova AS. Current possibilities of drug therapy for castration-resistant prostate cancer. Cancer Urology. 2013;9(2):73–

77. (In Russ.). https://doi.org/10.17650/1726-9776-2013-9-2-73-77, EDN: RAMIBL

4. Gallaher J, Cook LM, Gupta S, Araujo A, Dhillon J, Park JY, et al. Improving treatment strategies for patients with met-

astatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastasis. 2014

Dec;31(8):991–999. https://doi.org/10.1007/s10585-014-9674-1

5. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int

J Clin Pract. 2011 Nov;65(11):1180–1192. https://doi.org/10.1111/j.1742-1241.2011.02799.x

6. Matveev VB, Markova AS. Efficacy and safety of radium-223 in routine clinical practice. Cancer Urology. 2020;16(4):129–

135. (In Russ.). https://doi.org/10.17650/1726-9776-2020-16-4-129-135, EDN: OVEGET

7. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-

SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Eur Urol. 2021 Feb;79(2):243–262. https://doi.org/10.1016/j.eururo.2020.09.042

11

South Russian Journal of Cancer 2024. Vol. 5, No. 4. P. 6-13

Kit O. I., Maksimova N. A., Gusareva M. A., Shevchenko A. N., Zinkovich M. S., Ilchenko M. G., Boyko K. P., Faenson A. V., Dimitriadi S. N., Rozenko L. Ya. Intravenous

radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer

8. Keizman D, Fosboel MO, Reichegger H, Peer A, Rosenbaum E, Desax MC, et al. Imaging response during therapy with radi-

um-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):289–293. https://doi.org/10.1038/pcan.2017.6

9. Maksimova NA, Gusareva MA, Zinkovich MS, Faenson AV, Ilchenko MG, Kosheleva NG, et al. The first case of radium-223

use in patients with bone metastases of castration-resistant prostate cancer is a question of oncology. 2023;69(3S):232–

233. (In Russ.). https://doi.org/10.37469/0507-3758-2023-69-3s1, EDN: SBQKBK

10. Kochetova TYu, Krylov VV, Petrosyan KM, Karyakin OB, Biryukov VA, Alekseev BYa, et al. Radium chloride [223Ra] for pa-

tients with prostate cancer and skeletal metastases. Clinical recommendations. Cancer Urology. 2020;16(1):114–123.

(In Russ.). https://doi.org/10.17650/1726-9776-2020-16-1-114-123, EDN: UPRLFX

11. Kairemo K, Joensuu T, Rasulova N, Kiljunen T, Kangasmäki A. Evaluation of Alpha-Therapy with Radium-223-Dichloride in

Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics.

Diagnostics (Basel). 2015 Jul 30;5(3):358–368. https://doi.org/10.3390/diagnostics5030358

12. Xofigo (radium-223 dichloride). Summary of Product Characteristics. Bayer Inc., 2022.

https://www.bayer.com/sites/default/files/xofigo-pm-en.pdf

13. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castra-

tion-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

J Clin Oncol. 2014 Oct 20;32(30):3436–3448. https://doi.org/10.1200/JCO.2013.54.8404

Information about authors:

Oleg I. Kit – Academician at the Russian Academy of Sciences, Dr. Sci. (Med.), MD, professor, general director, National Medical Research Centre

for Oncology, Rostov-on-Don, Russian Federationn Federation

ORCID: https://orcid.org/0000-0003-3061-6108, SPIN: 1728-0329, AuthorID: 343182, ResearcherID: U-2241-2017, Scopus Author ID: 55994103100

Natalia A. Maksimova – Dr. Sci. (Med.), MD, Professor, Head of Department of Radionuclide Therapy and Diagnostics, National Medical Research

Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-0400-0302, SPIN: 1785-9046, AuthorID: 375005, ResearcherID: AAT-9775-2020, Scopus Author ID: 57211495326

Marina A. Gusareva – Cand. Sci. (Med.), MD, Head of Department of Radiology No. 1, National Medical Research Centre for Oncology,

Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-9426-9662, SPIN: 9040-5476, AuthorID: 705242

Alexey N. Shevchenko – Dr. Sci. (Med.), MD, Head of Department of Oncourology, National Medical Research Centre for Oncology, Rostov-on-Don,

Russian Federation

ORCID: https://orcid.org/0000-0002-9468-134X, SPIN: 2748-2638, AuthorID: 735424, ResearcherID: Y-5387-2018, Scopus Author ID: 57192283096

Mikhail S. Zinkovich – Cand. Sci. (Med.), MD, radiotherapist, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0003-2460-0038, SPIN: 1072-9674, AuthorID: 735168, ResearcherID: JGE-4158-2023

Maria G. Ilchenko  – Cand. Sci. (Med.), MD, Researcher at the Department of Tumor Diagnostics, National Medical Research Centre for Oncology,

Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-9126-0646, SPIN: 2856-7946, AuthorID: 734046, ResearcherID: ААТ-9807-2020

Konstantin P. Boyko – Cand. Sci. (Med.), MD, radiologist, Department of Radionuclide Therapy and Diagnostics, National Medical Research Centre

for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0003-1694-1385, SPIN: 4536-4073, AuthorID: 734382

Aleksandr V. Faenson – Cand. Sci. (Med.), MD, oncologist, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-3386-0491, SPIN: 4012-6345, AuthorID: 735389

Sergey N. Dimitriadi – Dr. Sci. (Med.), MD, senior researcher, Section of Urology, National Medical Research Centre for Oncology, Rostov-on-Don,

Russian Federation

ORCID: https://orcid.org/0000-0002-2565-1518, SPIN: 8337-8141, AuthorID: 692389, Scopus Author ID: 57076760200

12

Южно-Российский онкологический журнал 2024. Т. 5, № 4. С. 6-13

Кит О. И., Максимова Н. А., Гусарева М. А., Шевченко А. Н., Зинькович М. С., Ильченко М. Г., Бойко К. П., Фаенсон А. В., Димитриади С. Н., Розенко Л. Я.

Применение внутривенной радионуклидной терапии радия хлоридом [223Ra] у пациентов с костными метастазами кастрационно-резистентного рака

предстательной железы

Lyudmila Ya. Rozenko – Dr. Sci. (Med.), MD, Professor, radiotherapist, Department of Radiology No. 2, National Medical Research Centre for

Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0001-7032-8595, SPIN: 8879-2251, AuthorID: 421802, Scopus Author ID: 55397560100

Contribution of the authors:

Kit O. I. – scientific guidance, scientific editing;

Maksimova N. A. – study concept, scientific editing;

Gusareva M. A. – text editing, material collection;

Shevchenko A. N. – material collection and analysis;

Zinkovich M. S. – material analysis, manuscript writing;

Ilchenko M. G. – material analysis, text design;

Boyko K. P. – material collection;

Faenson A. V. – material collection;

Dimitriadi S. N. – material collection and analysis;

Rozenko L. Ya. – material collection and analysis.

13